Price | 0.26 | EPS | -3 | |
Shares | 9 | P/E | -0 | |
MCap | 2 | P/FCF | -0 | |
Net Debt | -20 | EBIT | -23 | |
TEV | -18 | TEV/EBIT | 1 | TTM 2019-09-30, in MM, except price, ratios |
10-Q | 2020-09-30 | Filed 2020-11-13 |
10-Q | 2020-06-30 | Filed 2020-08-13 |
10-Q | 2020-03-31 | Filed 2020-05-13 |
10-K | 2019-12-31 | Filed 2020-03-25 |
S-1 | 2019-12-11 | Public Filing |
10-Q | 2019-09-30 | Filed 2019-11-06 |
S-1 | 2019-07-26 | Public Filing |
10-Q | 2019-06-30 | Filed 2019-08-14 |
10-Q | 2019-03-31 | Filed 2019-05-08 |
10-K | 2018-12-31 | Filed 2019-04-01 |
S-1 | 2018-12-27 | Public Filing |
10-Q | 2018-09-30 | Filed 2018-11-07 |
10-Q | 2018-06-30 | Filed 2018-08-08 |
10-Q | 2018-03-31 | Filed 2018-05-09 |
10-K | 2017-12-31 | Filed 2018-03-20 |
10-Q | 2017-09-30 | Filed 2017-11-09 |
10-Q | 2017-06-30 | Filed 2017-08-10 |
10-Q | 2017-03-31 | Filed 2017-05-10 |
10-K | 2016-12-31 | Filed 2017-03-08 |
10-Q | 2016-09-30 | Filed 2016-11-10 |
10-Q | 2016-06-30 | Filed 2016-08-09 |
10-Q | 2016-03-31 | Filed 2016-05-10 |
10-K | 2015-12-31 | Filed 2016-03-08 |
10-Q | 2015-09-30 | Filed 2015-11-05 |
10-Q | 2015-06-30 | Filed 2015-08-11 |
10-Q | 2015-03-31 | Filed 2015-06-25 |
8-K | 2020-11-12 | |
8-K | 2020-11-12 | |
8-K | 2020-08-13 | |
8-K | 2020-07-06 | |
8-K | 2020-07-06 | |
8-K | 2020-06-26 | |
8-K | 2020-06-01 | |
8-K | 2020-05-14 | |
8-K | 2020-05-14 | |
8-K | 2020-05-13 | |
8-K | 2020-04-16 | |
8-K | 2020-03-25 | |
8-K | 2019-11-06 | |
8-K | 2019-09-27 | |
8-K | 2019-09-11 | |
8-K | 2019-09-05 | |
8-K | 2019-08-22 | |
8-K | 2019-08-14 | |
8-K | 2019-08-05 | |
8-K | 2019-06-12 | |
8-K | 2019-06-03 | |
8-K | 2019-05-20 | |
8-K | 2019-05-08 | |
8-K | 2019-03-27 | |
8-K | 2019-02-28 | |
8-K | 2019-02-13 | |
8-K | 2018-11-07 | |
8-K | 2018-08-08 | |
8-K | 2018-07-31 | |
8-K | 2018-06-11 | |
8-K | 2018-06-06 | |
8-K | 2018-05-12 | |
8-K | 2018-05-09 | |
8-K | 2018-05-07 | |
8-K | 2018-05-02 | |
8-K | 2018-03-20 | |
8-K | 2018-03-19 | |
8-K | 2018-01-19 |
Item 1. Condensed Consolidated Financial Statements |
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations |
Item 3: Quantitative and Qualitative Disclosures About Market Risk |
Item 4: Controls and Procedures |
Part II. Other Information |
Item 1. Legal Proceedings |
Item 1A. Risk Factors |
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds |
Item 3. Defaults Upon Senior Securities |
Item 4. Mine Safety Disclosures |
Item 5. Other Information |
Item 6. Exhibits |
EX-31.1 | rkda-ex311_8.htm |
EX-31.2 | rkda-ex312_10.htm |
EX-32.1 | rkda-ex321_6.htm |
EX-32.2 | rkda-ex322_9.htm |
Balance Sheet | Income Statement | Cash Flow |
---|---|---|
Assets, Equity
|
Rev, G Profit, Net Income
|
Ops, Inv, Fin
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2020
OR
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 001-37383
Arcadia Biosciences, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 81-0571538 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer |
202 Cousteau Place, Suite 105 Davis, CA | 95618 |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (530) 756-7077
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common | RKDA | NASDAQ CAPITAL MARKET |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 11, 2020, the registrant had 10,832,203 shares of common stock outstanding, $0.001 par value per share.
FORM 10-Q FOR THE QUARTER ENDED September 30, 2020
INDEX
|
|
|
|
|
| Page |
Part I — |
|
| 1 | |||
|
|
|
|
| ||
|
| Item 1. |
|
| 1 | |
|
|
|
|
| ||
|
|
|
|
| 1 | |
|
|
|
|
| ||
|
|
|
| Condensed Consolidated Statements of Operations and Comprehensive Loss |
| 2 |
|
|
|
|
|
|
|
|
|
|
|
| 3 | |
|
|
|
|
| ||
|
|
|
|
| 5 | |
|
|
|
|
| ||
|
|
|
|
| 6 | |
|
|
|
|
| ||
|
| Item 2. |
| Management’s Discussion and Analysis of Financial Condition and Results of Operations |
| 24 |
|
|
|
|
| ||
|
| Item 3. |
|
| 35 | |
|
|
|
|
| ||
|
| Item 4. |
|
| 35 | |
|
|
|
| |||
Part II — |
|
| 36 | |||
|
|
|
|
| ||
|
| Item 1. |
|
| 36 | |
|
|
|
|
| ||
|
| Item 1A. |
|
| 36 | |
|
|
|
|
| ||
|
| Item 2. |
|
| 36 | |
|
|
|
|
| ||
|
| Item 3. |
|
| 36 | |
|
|
|
|
| ||
|
| Item 4. |
|
| 36 | |
|
|
|
|
| ||
|
| Item 5. |
|
| 36 | |
|
|
|
|
| ||
|
| Item 6. |
|
| 37 | |
|
|
|
|
|
|
|
| 38 |
Arcadia Biosciences, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands, except share data)
|
| September 30, 2020 |
|
| December 31, 2019 |
| ||
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
| $ | 10,201 |
|
| $ | 8,417 |
|
Short-term investments |
|
| — |
|
|
| 16,915 |
|
Accounts receivable |
|
| 373 |
|
|
| 602 |
|
Inventories, net — current |
|
| 9,416 |
|
|
| 1,794 |
|
Prepaid expenses and other current assets |
|
| 1,204 |
|
|
| 712 |
|
Total current assets |
|
| 21,194 |
|
|
| 28,440 |
|
Restricted cash |
|
| 2,001 |
|
|
| — |
|
Property and equipment, net |
|
| 3,484 |
|
|
| 1,799 |
|
Right of use asset |
|
| 6,013 |
|
|
| 1,963 |
|
Inventories, net — noncurrent |
|
| 461 |
|
|
| 364 |
|
Goodwill |
|
| 301 |
|
|
| - |
|
Intangible assets, net |
|
| 400 |
|
|
| - |
|
Other noncurrent assets |
|
| 23 |
|
|
| 8 |
|
Total assets |
| $ | 33,877 |
|
| $ | 32,574 |
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
| $ | 6,711 |
|
| $ | 4,685 |
|
Amounts due to related parties |
|
| 29 |
|
|
| 40 |
|
Debt — current |
|
| 705 |
|
|
| 24 |
|
Unearned revenue — current |
|
| — |
|
|
| 42 |
|
Operating lease liability — current |
|
| 700 |
|
|
| 611 |
|
Other current liabilities |
|
| 263 |
|
|
| 306 |
|
Total current liabilities |
|
| 8,408 |
|
|
| 5,708 |
|
Debt — noncurrent |
|
| 2,548 |
|
|
| 107 |
|
Operating lease liability — noncurrent |
|
| 5,574 |
|
|
| 1,497 |
|
Common stock warrant liabilities |
|
| 3,065 |
|
|
| 14,936 |
|
Other noncurrent liabilities |
|
| 2,280 |
|
|
| 2,000 |
|
Total liabilities |
|
| 21,875 |
|
|
| 24,248 |
|
Commitments and contingencies (Note 14) |
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
Common stock, $0.001 par value—150,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 10,832,203 and 8,646,149 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively |
|
| 51 |
|
|
| 49 |
|
Additional paid-in capital |
|
| 231,954 |
|
|
| 214,826 |
|
Accumulated other comprehensive income |
|
| — |
|
|
| 1 |
|
Accumulated deficit |
|
| (220,725 | ) |
|
| (207,171 | ) |
Total Arcadia Biosciences stockholders’ equity |
|
| 11,280 |
|
|
| 7,705 |
|
Non-controlling interest |
|
| 722 |
|
|
| 621 |
|
Total stockholders' equity |
|
| 12,002 |
|
|
| 8,326 |
|
Total liabilities and stockholders’ equity |
| $ | 33,877 |
|
| $ | 32,574 |
|
See accompanying notes to the unaudited condensed consolidated financial statements.
1
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except share and per share data)
|
| Three Months Ended September 30, |
| Nine Months Ended September 30, |
| ||||||||||
|
|
| 2020 |
|
|
| 2019 |
|
| 2020 |
|
|
| 2019 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product |
| $ | 245 |
|
| $ | 216 |
| $ | 630 |
|
| $ | 485 |
|
License |
|
| 10 |
|
|
| 17 |
|
| 110 |
|
|
| 17 |
|
Royalty |
|
| 16 |
|
|
| — |
|
| 58 |
|
|
| — |
|
Contract research and government grants |
|
| 43 |
|
|
| 159 |
|
| 106 |
|
|
| 251 |
|
Total revenues |
|
| 314 |
|
|
| 392 |
|
| 904 |
|
|
| 753 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenues |
|
| 1,841 |
|
|
| 177 |
|
| 3,463 |
|
|
| 324 |
|
Research and development |
|
| 1,762 |
|
|
| 1,931 |
|
| 5,999 |
|
|
| 5,387 |
|
Selling, general and administrative |
|
| 4,292 |
|
|
| 4,477 |
|
| 11,689 |
|
|
| 10,434 |
|
Total operating expenses |
|
| 7,895 |
|
|
| 6,585 |
|
| 21,151 |
|
|
| 16,145 |
|
Loss from operations |
|
| (7,581 | ) |
|
| (6,193 | ) |
| (20,247 | ) |
|
| (15,392 | ) |
Interest expense |
|
| (23 | ) |
|
| (3 | ) |
| (32 | ) |
|
| (3 | ) |
Other income, net |
|
| — |
|
|
| 119 |
|
| 83 |
|
|
| 339 |
|
Change in fair value of common stock warrant liabilities |
|
| 1,130 |
|
|
| (7,777 | ) |
| 6,212 |
|
|
| (6,790 | ) |
Loss on extinguishment of warrant liability |
|
| (682 | ) |
|
| — |
|
| (635 | ) |
|
| — |
|
Offering costs |
|
| — |
|
|
| (336 | ) |
| — |
|
|
| (702 | ) |
Net loss before income taxes |
|
| (7,156 | ) |
|
| (14,190 | ) |
| (14,619 | ) |
|
| (22,548 | ) |
Income tax benefit (provision) |
|
| (9 | ) |
|
| 3 |
|
| (15 | ) |
|
| (14 | ) |
Net loss |
|
| (7,165 | ) |
|
| (14,187 | ) |
| (14,634 | ) |
|
| (22,562 | ) |
Net loss attributable to non-controlling interest |
|
| (774 | ) |
|
| — |
|
| (1,081 | ) |
|
| — |
|
Net loss attributable to common stockholders |
| $ | (6,391 | ) |
| $ | (14,187 | ) | $ | (13,553 | ) |
| $ | (22,562 | ) |
Net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
| $ | (0.60 | ) |
| $ | (2.04 | ) | $ | (1.42 | ) |
| $ | (4.03 | ) |
Weighted-average number of shares used in per share calculations: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and Diluted |
|
| 10,719,618 |
|
|
| 6,942,612 |
|
| 9,570,259 |
|
|
| 5,596,545 |
|
Other comprehensive loss, net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized losses on available-for-sale securities |
|
| — |
|
|
| (1 | ) |
| (1 | ) |
|
| — |
|
Other comprehensive loss |
|
| — |
|
|
| (1 | ) |
| (1 | ) |
|
| — |
|
Comprehensive loss attributable to common stockholders |
| $ | (6,391 | ) |
| $ | (14,188 | ) | $ | (13,554 | ) |
| $ | (22,562 | ) |
See accompanying notes to the unaudited condensed consolidated financial statements.
2
Condensed Consolidated Statements of Stockholders’ Equity
(Unaudited)
(In thousands, except share data)
|
| Common Stock |
|
| Additional Paid-In |
|
| Accumulated |
|
| Accumulated Other Comprehensive |
|
| Non- Controlling |
|
| Total Stockholders’ |
| ||||||||||
|
| Shares |
|
| Amount |
|
| Capital |
|
| Deficit |
|
| (Loss) Income |
|
| Interest |
|
| Equity |
| |||||||
Balance at December 31, 2019 |
|
| 8,646,149 |
|
| $ | 49 |
|
| $ | 214,826 |
|
| $ | (207,171 | ) |
| $ | 1 |
|
| $ | 621 |
|
| $ | 8,326 |
|
Issuance of shares related to employee stock purchase plan |
|
| 7,946 |
|
|
| — |
|
|
| 14 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 14 |
|
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 772 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 772 |
|
Unrealized losses on available-for-sale securities |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (1 | ) |
|
| — |
|
|
| (1 | ) |
Non-controlling interest contributions |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 689 |
|
|
| 689 |
|
Net (loss) income |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 2,525 |
|
|
| — |
|
|
| (102 | ) |
|
| 2,423 |
|
Balance at March 31, 2020 |
|
| 8,654,095 |
|
| $ | 49 |
|
| $ | 215,612 |
|
| $ | (204,646 | ) |
| $ | — |
|
| $ | 1,208 |
|
| $ | 12,223 |
|
Issuance of shares related to exercise of June 2018 Warrants |
|
| 1,392,345 |
|
|
| 1 |
|
|
| 5,568 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 5,569 |
|
Issuance of investor warrants related to May 2020 Warrant Transaction |
|
| — |
|
|
| — |
|
|
| 4,415 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 4,415 |
|
Issuance of placement agent warrants related to issuance of May 2020 Warrants |
|
| — |
|
|
| — |
|
|
| 215 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 215 |
|
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 595 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 595 |
|
Non-controlling interest contributions |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 493 |
|
|
| 493 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (9,688 | ) |
|
| — |
|
|
| (205 | ) |
|
| (9,893 | ) |
Balance at June 30, 2020 |
|
| 10,046,440 |
|
| $ | 50 |
|
| $ | 226,405 |
|
| $ | (214,334 | ) |
| $ | — |
|
| $ | 1,496 |
|
| $ | 13,617 |
|
Issuance of shares related to exercise of March 2018 PIPE |
|
| 641,416 |
|
|
| 1 |
|
|
| 2,443 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 2,444 |
|
Issuance of investor warrants related to July 2020 Warrant Transaction |
|
| — |
|
|
| — |
|
|
| 2,059 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 2,059 |
|
Issuance of placement agent warrants related to issuance of July 2020 Warrants |
|
| — |
|
|
| — |
|
|
| 101 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 101 |
|
Issuance of shares related to employee stock purchase plan |
|
| 11,721 |
|
|
| — |
|
|
| 37 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 37 |
|
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 477 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 477 |
|
Shares of common stock issued at closing of ISI transaction |
|
| 132,626 |
|
|
| — |
|
|
| 432 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 432 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (6,391 | ) |
|
| — |
|
|
| (774 | ) |
|
| (7,165 | ) |
Balance at September 30, 2020 |
|
| 10,832,203 |
|
| $ | 51 |
|
| $ | 231,954 |
|
| $ | (220,725 | ) |
| $ | — |
|
| $ | 722 |
|
| $ | 12,002 |
|
3
| Common Stock |
|
| Additional Paid-In |
|
| Accumulated |
|
| Non- Controlling |
|
| Total Stockholders’ |
| ||||||||||
|
| Shares |
|
| Amount |
|
| Capital |
|
| Deficit |
|
| Interest |
|
| Equity |
| ||||||
Balance at December 31, 2018 |
|
| 4,774,919 |
|
| $ | 45 |
|
| $ | 191,136 |
|
| $ | (178,366 | ) |
| $ | — |
|
| $ | 12,815 |
|
Issuance of shares related to employee stock purchase plan |
|
| 2,500 |
|
|
| — |
|
|
| 8 |
|
|
| — |
|
|
| — |
|
|
| 8 |
|
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 422 |
|
|
| — |
|
|
| — |
|
|
| 422 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (12,612 | ) |
|
| — |
|
|
| (12,612 | ) |
Balance at March 31, 2019 |
|
| 4,777,419 |
|
| $ | 45 |
|
| $ | 191,566 |
|
| $ | (190,978 | ) |
| $ | — |
|
| $ | 633 |
|
Issuance of shares related to June 2019 Offering |
|
| 1,489,575 |
|
|
| 2 |
|
|
| 3,301 |
|
|
| — |
|
|
| — |
|
|
| 3,303 |
|
Issuance of placement agent warrants related to June 2019 Offering |
|
| — |
|
|
| — |
|
|
| 198 |
|
|
| — |
|
|
| — |
|
|
| 198 |
|
Issuance of shares related to the exercise of warrants issued with the June 2019 offering |
|
| 1,053,745 |
|
|
| 1 |
|
|
| 5,268 |
|
|
| — |
|
|
| — |
|
|
| 5,269 |
|
Offering costs related to June 2019 Offering |
|
| — |
|
|
| — |
|
|
| (487 | ) |
|
| — |
|
|
| — |
|
|
| (487 | ) |
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 389 |
|
|
| — |
|
|
| — |
|
|
| 389 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 4,237 |
|
|
| — |
|
|
| 4,237 |
|
Balance at June 30, 2019 |
|
| 7,320,739 |
|
| $ | 48 |
|
| $ | 200,235 |
|
| $ | (186,741 | ) |
| $ | — |
|
| $ | 13,542 |
|
Issuance of shares related to employee stock purchase plan |
|
| 6,036 |
|
|
| — |
|
|
| 10 |
|
|
| — |
|
|
| — |
|
|
| 10 |
|
Issuance of shares related to employee stock option exercises |
|
| 546 |
|
|
| — |
|
|
| 3 |
|
|
| — |
|
|
| — |
|
|
| 3 |
|
Reclassification of common stock warrant liability balance with exercise |
|
| — |
|
|
| — |
|
|
| 7,016 |
|
|
| — |
|
|
| — |
|
|
| 7,016 |
|
Issuance of shares related to September 2019 Offering |
|
| 1,318,828 |
|
|
| 1 |
|
|
| 6,570 |
|
|
| — |
|
|
| — |
|
|
| 6,571 |
|
Issuance of placement agent warrants related to September 2019 Offering |
|
| — |
|
|
| — |
|
|
| 326 |
|
|
| — |
|
|
| — |
|
|
| 326 |
|
Offering costs related to September 2019 Offering |
|
| — |
|
|
| — |
|
|
| (796 | ) |
|
| — |
|
|
| — |
|
|
| (796 | ) |
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 1,059 |
|
|
| — |
|
|
| — |
|
|
| 1,059 |
|
Non-controlling interest contributions |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 689 |
|
|
| 689 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (14,187 | ) |
|
| — |
|
|
| (14,187 | ) |
Balance at September 30, 2019 |
|
| 8,646,149 |
|